Our Response to COVID-19
We’re committed to being the best partner to support ongoing developments in the treatment and prevention of COVID-19.
COVID-19 vaccine priorities
Empowering our customers:
- As part of the Federal Retail Pharmacy program, Good Neighbor Pharmacy members began vaccine administration on February 11, 2011
- Ensuring access and advocating for administration and reimbursement for independent pharmacies
- Continuing clear and iterative communications
Preparing our operations:
- Enhancing strategic capability investments
- Appropriately resourcing our internal task force
- Engaging in cross-functional collaboration
Educating our partners:
- Collaborating with federal and state agencies
- Partnering with industry groups
COVID-19 vaccine timeline
March 2020
World Courier provides storage and logistics for vaccine trials
November 2020
Good Neighbor Pharmacy and Elevate Provider Network included in CDC’s Federal Retail Pharmacy Program for vaccine administration
December 2020
Innomar Strategies selected to support the distribution of vaccines across Canada
December 2020
World Courier supports vaccine distribution across the globe
February 2021
Good Neighbor Pharmacy members start administering COVID-19 vaccine as part of Federal Retail Pharmacy Program Phase II
May 2021
Good Neighbor Pharmacy surpasses 1 million doses of COVID-19 vaccines allocated through Federal Retail Pharmacy Program
September 2021
Good Neighbor Pharmacy surpasses 2 million doses of COVID-19 vaccines allocated through Federal Retail Pharmacy Program
COVID-19 therapies priorities
Innovation continues...
- Engaged with the U.S. government and pharmaceutical manufacturers to support the distribution of every COVID-19 therapy that has received emergency use authorization (EUA) from the FDA.
- Remain involved in providing metrics and key data directly to the HHS, CDC, and other agencies within the Federal Government and state agencies.
- Continue to support multiple stakeholder meetings to share expertise regarding logistics and operations.
COVID-19 treatment timeline
May 2020
FDA issued Emergency Use Authorization to
Gilead for Veklury (Remdesivir),
AmerisourceBergen selected as sole distributor
October 2020
Veklury (Remdesivir) becomes the first COVID-19 treatment approved by the FDA
November 2020
FDA issued Emergency Use Authorization to Regeneron for Casirivimab and Imdevimab antibody cocktail, AmerisourceBergen selected as sole distributor
November 2020
FDA issued Emergency Use Authorization to Eli Lilly and Company for Bamlanivimab, AmerisourceBergen selected as sole distributor
April 2021
FDA revokes Emergency Use Authorization of Bamlanivimab mono
Eli Lilly's combo therapy of Bamlanivimab & Etesevimab is not revoked.
May 2021
FDA issued Emergency Use Authorization to GSK for sotrovimab, AmerisourceBergen selected as sole distributor
July 2021
1 million+ patient antibody courses of COVID-19 therapies shipped by AmerisourceBergen
Since the start of our partnership with the HHS, AmerisourceBergen has shipped over one million patient courses of COVID-19 therapies to sites of care throughout the U.S.
October 2021
U.S. Government procured GSK’s full supply of sotrovimab, AmerisourceBergen selected to distribute on behalf of the government
December 2021
FDA issued Emergency Use Authorization for Merck's Lagevrio/Molnupiravir. AmerisourceBergen selected as sole distributor
December 2021
FDA issued Emergency Use Authorization for AstraZeneca's AZD-7442. AmerisourceBergen selected as sole distributor
December 2021
FDA issued Emergency Use Authorization to Pfizer for Paxlovid, AmerisourceBergen selected as sole distributor